Acute upper gastrointestinal bleeding in octogenarians: Clinical outcome and factors related to mortality

Table 1 Clinicoepidemiological characteristics of patients with acute upper gastrointestinal bleeding

	Group A (65-80 yr)	Group B (> 80 yr)	P (95% CI)
Female, n (%)	83/269 (30.8)	65/147 (44,2)	0.009 (0.37-0.85)
Inpatients with AUGIB, n (%)	20/269 (7.4)	9/147 (6.1)	NS
History of ulcer disease/bleeding, n (%)	81/269 (30.1)	48/147 (32.6)	NS
Heart rate (on admission), (mean ± SD)	86.8 ± 19.5	87.4 ± 15.7	NS
Blood Pressure(on admission), (mean ± SD)	122.6 ± 21.1	124.3 ± 25	NS
Presence of hematemesis, n (%)	68/269 (25.3)	21/147 (14.3)	0.012 (1.18-3.47)
Presence of shock on admission, n (%)	24 (4.9)	10 (2.8)	NS
Hematocrit (on admission), (mean ± SD)	30 ± 7.3	28.5 ± 7.2	0.047
Creatinine (on admission), (mean ± SD)	1.3 ± 0.8	1.5 ± 0.9	0.006
Urea (on admission), (mean ± SD)	85.0 ± 55	105.0 ± 66.0	0.001
Recent NSAIDs use, n (%)	152/269 (56.5)	79/147 (53.7)	NS
Recent aspirin use, n (%)	101/269 (37.5)	58/147 (39.4)	NS
Oral-anticoagulants use, n (%)	34/269 (12.6)	10/147 (6.8)	NS
Antiplatelet drugs use, n (%)	53/269 (19.7)	23/147 (15.6)	NS
Combined use of NSAIDs and antiplatelet drugs, n (%)	28/269 (10.4)	3/147 (2.0)	0.004 (1.7-18.7)
Combined use of NSAIDs and oral anticoagulants, n (%)	10/269 (3.7)	1/147 (0.6)	NS

AUGIB: Acute upper gastrointestinal bleeding; NSAIDs: Non-steroidal anti-inflammatory drugs; NS: No significance.